A thrombus is a blood clot that forms inside a blood vessel and stays where it formed. An embolus is any object, most often a piece of that same clot, that breaks free, travels through the bloodstream, and lodges somewhere downstream. The relationship between the two is sequential: a thrombus can become an embolus if it detaches, but not every thrombus does, and not every embolus started as a clot. Understanding where and why clots form, what makes them break loose, and what happens when they land in a new location is central to preventing some of the most common causes of stroke, heart attack, and sudden death.
How a Thrombus Forms
Blood clots inside vessels form when the body’s clotting system activates in a place it shouldn’t, or activates too aggressively. The classic framework for understanding this goes back to the 1800s, when the pathologist Rudolf Virchow identified three broad conditions that promote clot formation: damage to the blood vessel wall, sluggish or abnormal blood flow, and changes in the blood itself that make it more prone to clotting.1PubMed Central. Procoagulant activity in hemostasis and thrombosis: Virchow’s triad revisited Virchow also described how clot material could travel from a vein to the brain and cause a stroke, an insight that took decades for the medical world to fully accept.2PubMed. Rudolf Virchow and the Discovery of Cerebral Embolism
In practice, many thrombi involve more than one of those three conditions acting at the same time. A person immobilized after surgery, for instance, has sluggish blood flow in the deep veins of the legs. If they also have a genetic tendency toward hypercoagulable blood, the risk compounds. The clot that results is a tangled mass of fibrin protein, blood cells, and platelets, physically attached to the vessel wall.
Arterial Clots and Venous Clots Are Not the Same Thing
One of the most practically important distinctions is that clots forming in arteries look and behave differently from those forming in veins. Arterial thrombi, like those found in blocked coronary arteries during heart attacks, are dense, tightly packed structures dominated by fibrin and platelets. In one detailed structural analysis, arterial clots were roughly 43% fibrin and 31% platelets by volume, with relatively few red blood cells.3Scientific Reports. The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli They form in high-flow, high-pressure environments where platelets stick to damaged vessel walls and rapidly accumulate.
Venous thrombi, by contrast, form in slower-moving blood and are loaded with red blood cells and fibrin, with far fewer platelets. That same analysis found venous clots averaged about 63% red blood cells and 35% fibrin, with platelets making up less than 1% of the volume. This is why venous clots often appear dark red, while arterial clots tend to look pale or grayish-white. The distinction matters for treatment: drugs that target platelets are the backbone of arterial clot management, while anticoagulants that slow fibrin formation are first-line therapy for venous clots.
Stroke clots add a wrinkle. Thrombi retrieved from patients with acute ischemic stroke tend to show both red-blood-cell-rich and platelet-rich zones, which makes sense given that many strokes are caused by emboli that originated somewhere else and may have mixed characteristics.4PubMed Central. Thrombus Structural Composition in Cardiovascular Disease
What Makes a Thrombus Break Free
The transition from thrombus to embolus happens when part or all of a clot detaches from the vessel wall and enters the bloodstream. People often assume that fast-moving blood shearing across the clot surface is what rips it loose, but recent modeling work suggests that isn’t the main driver. A 2024 computational study found that wall stretch, the force transmitted through the vessel wall as it expands with each heartbeat, and blood pressure are more likely to be critical embolization forces, while shear stress alone, even when severely elevated, appears unlikely to dislodge a clot.5PubMed. “What makes blood clots break off?” A Back-of-the-Envelope Computation Toward Explaining Clot Embolization
At the material level, clot rupture works like tearing a piece of fabric: individual fibrin fibers ahead of a crack stretch until they break, and once enough fibers fail, a fragment detaches. Simulations modeling fibrin’s mechanical properties confirmed that this fiber-level stretching and breaking is the mechanism underlying thrombotic embolization.6PubMed Central. Rupture of blood clots: Mechanics and pathophysiology The fragment, now an embolus, is carried wherever the blood takes it, typically lodging in the first vessel too narrow for it to pass through.
Venous Thromboembolism as One Disease
Doctors increasingly treat deep vein thrombosis (DVT) and pulmonary embolism (PE) as two faces of the same condition, called venous thromboembolism (VTE). A pulmonary embolism is considered to originate from embolization of a deep vein clot, which makes the two events manifestations of one underlying disease rather than separate diagnoses.7PubMed Central. Finding the origin of pulmonary emboli with a total-body magnetic resonance direct thrombus imaging technique The thrombus forms in a deep vein, often near a venous valve pocket in the leg or pelvis, and if it detaches, the embolus follows the venous return through larger and larger veins until it reaches the right side of the heart. From there it enters the pulmonary arteries, where the vessels narrow quickly and the fragment gets stuck.
Animal models have reinforced this picture. In one study designed to replicate human VTE, researchers formed clots in the femoral vein at a valve pocket, then released them and observed spontaneous pulmonary emboli composed of fibrin-rich material, mirroring what happens in patients.8PubMed Central. In Vivo Imaging of Venous Thrombus and Pulmonary Embolism Using Novel Murine Venous Thromboembolism Model
The size of the embolus determines how much of the lung’s circulation it blocks. A small embolus may be clinically silent; a massive one can obstruct the main pulmonary arteries, overwhelm the right ventricle, and cause sudden cardiovascular collapse. Treatment for massive PE has traditionally centered on heparin to prevent clot growth, but there is ongoing debate about whether thrombolytic drugs, which actively dissolve the clot, offer a meaningful advantage. Thrombolytics can clear the blockage faster but carry a higher risk of serious bleeding.9PubMed Central. Thrombolysis vs Anticoagulation: Unveiling the Trade-Offs in Massive Pulmonary Embolism For patients at high bleeding risk, catheter-based interventions or surgical removal of the clot are alternatives.10Journal of Vascular Surgery: Venous and Lymphatic Disorders. Catheter-directed interventions versus surgical embolectomy in massive pulmonary embolism
When the Heart Is the Source
Not all emboli come from leg veins. The heart itself is a common origin, especially in people with atrial fibrillation (AF). During AF, the upper chambers of the heart quiver instead of contracting effectively, which allows blood to pool and stagnate. This stasis is most pronounced in a small pouch called the left atrial appendage, whose shape and internal ridges make it a natural pocket for slow-moving blood. That stagnant blood can form a thrombus, and if a fragment breaks off, it enters the arterial circulation directly.11PubMed Central. The Left Atrial Appendage and Atrial Fibrillation-A Contemporary Review
Because the left atrial appendage empties into the aorta, emboli from this location can travel anywhere arterial blood goes: the brain, kidneys, spleen, intestines, or limbs. The brain is the most feared destination. Stroke associated with atrial fibrillation is largely attributed to embolism of thrombus formed during stasis in the left atrial appendage.12PubMed. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation This is why blood thinners are standard for most people with AF, even if they feel fine otherwise. Detecting cardiac thrombi can be done with CT angiography or echocardiography; one meta-analysis found CT angiography picked up thrombi in about 6% of stroke patients compared to about 5% by transesophageal echo, with CT showing high sensitivity and specificity when the two were compared head to head.13PubMed Central. CT angiography vs echocardiography for detection of cardiac thrombi in ischemic stroke: a systematic review and meta-analysis
Paradoxical Embolism and the Patent Foramen Ovale
There is a route by which a venous clot can cause an arterial stroke, even without atrial fibrillation. About a quarter of all adults have a patent foramen ovale (PFO), a small opening between the right and left atria that is a normal part of fetal circulation and typically closes after birth but never fully seals in these individuals. If a clot from the venous system reaches the right atrium and the PFO is open, the fragment can cross to the left side of the heart and enter the arterial circulation. This is called paradoxical embolism, and it accounts for roughly 5% of all strokes and about 10% of strokes in younger patients.14JAMA. Patent Foramen Ovale and Stroke: A Review
Paradoxical embolism is one of the reasons doctors investigate younger stroke patients aggressively for a PFO, especially when no other obvious cause is found. In selected patients, closure of the PFO with a catheter-deployed device can reduce the risk of recurrent stroke.
Emboli That Are Not Blood Clots
The word “embolus” does not require a blood clot. Any material that travels through the bloodstream and blocks a vessel qualifies. The most common non-thrombotic sources include fat (typically released after long bone fractures), air or gas (from surgical mishaps or diving accidents), amniotic fluid (a rare obstetric emergency), tumor cells, and foreign material like catheter fragments or injected substances.15PubMed Central. Nontrombotic Pulmonary Embolism: Different Etiology, Same Significant Consequences Septic emboli, composed of infected material often originating from heart valve vegetations, represent another category.
Non-thrombotic pulmonary embolism can be defined as partial or total blockage of the pulmonary circulation by any of these agents.16PubMed. Pathophysiology, clinics and diagnostics of non-thrombotic pulmonary embolism These events are far less common than thrombotic PE, but they are clinically significant because standard anticoagulant therapy does not help and the underlying cause demands entirely different treatment. A fat embolism after a femur fracture, for example, is managed with supportive care and fracture stabilization, while a septic embolism from endocarditis requires antibiotics and sometimes surgery to replace the infected valve.
Why Cancer Raises the Risk of Both
Cancer is one of the strongest acquired risk factors for abnormal clotting, and the relationship runs in both directions: cancer promotes thrombosis, and thrombosis sometimes reveals an undiagnosed cancer. The mechanisms are varied. Tumors can compress blood vessels directly, creating stasis. They secrete enzymes like heparanase that degrade the body’s natural anticoagulant defenses. And certain cancers release procoagulant factors that tip the balance of the clotting cascade toward excessive clot formation.17PubMed Central. Potential Mechanisms of Cancer-Related Hypercoagulability Patients with poor performance status, meaning those who are sicker and less mobile, face higher VTE risk. Cancer treatment itself, including chemotherapy and central venous catheters, adds further risk.
Beyond cancer, inherited genetic variants can shift a person toward excessive clotting throughout life. The Factor V Leiden mutation, for example, makes a key clotting factor resistant to the protein that normally switches it off, resulting in a chronic tendency toward hypercoagulable blood. A mutation in the prothrombin gene can increase levels of prothrombin, another clotting protein, with a similar effect.18Heliyon. Blood hypercoagulability and thrombosis mechanisms in cancer patients -A brief review People with these mutations may form clots in situations where others would not, and their clots may be more prone to embolization simply because they occur more frequently.
How Pathologists Tell a Real Clot from a Postmortem Artifact
When examining tissue after death, pathologists need to distinguish a thrombus that formed while the patient was alive from a clot that formed after the heart stopped. The classic teaching relies on structures called lines of Zahn, alternating layers of pale platelets and darker red blood cells that indicate the clot built up incrementally in flowing blood, something that cannot happen in stagnant postmortem blood. A 2023 study refined this picture, finding that thick bands of nested platelets wrapped in fibrin were nearly exclusive to clots formed before death, while postmortem clots showed thinner, less organized fibrin strands without the same platelet banding.19PubMed. Histologic and Immunohistochemical Features of Antemortem Thrombus Compared to Postmortem Clot: Updating the Definition of Lines of Zahn This distinction can be critical in forensic and autopsy settings where the cause of death hinges on whether a clot was present before cardiac arrest.
Long-Term Consequences After a Clot Event
Surviving a thromboembolism does not always mean the story is over. Two chronic conditions can develop as late consequences. Post-thrombotic syndrome (PTS) follows a deep vein thrombosis and involves persistent leg pain, swelling, skin changes, and in severe cases, ulceration of the skin around the ankle. The clot damages the vein’s valves, leading to chronic backflow of blood and elevated venous pressure. Chronic thromboembolic pulmonary hypertension (CTEPH) follows a pulmonary embolism that does not fully resolve: organized clot material remains in the pulmonary arteries, progressively raising the pressure the right side of the heart must work against. Symptoms range from breathlessness with exertion to overt right heart failure.20PubMed. Post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension: diagnosis and management
Both PTS and CTEPH are recognized as late complications of venous thromboembolism and are a major reason clinicians emphasize adequate anticoagulation duration and follow-up after a clot event.21PubMed. Prevention and treatment of the post-thrombotic syndrome and of the chronic thromboembolic pulmonary hypertension CTEPH is potentially curable with a specialized surgery called pulmonary endarterectomy, but it requires early recognition, and many cases go undiagnosed for months or years because the symptoms overlap with common conditions like deconditioning or asthma.
Clotting Differences in Children
Children are not simply small adults when it comes to clotting. Compared with adult blood, younger populations generate thrombin more slowly and in smaller amounts, meaning their blood takes longer to form a stable clot. Fibrin formation is also slower, and the resulting clot structure has significantly larger pores, making it less resistant to the body’s natural clot-dissolving mechanisms.22PubMed. Differences in the mechanism of blood clot formation and nanostructure in infants and children compared with adults In practical terms, this means children are naturally somewhat protected against pathological clot formation, which is one reason venous thromboembolism is rare in pediatric patients compared to older adults. When it does occur, it is usually triggered by strong external factors: central venous catheters, major surgery, prolonged immobility, or underlying conditions like congenital heart disease.
Why Animal Models Do Not Always Match Human Clotting
Much of what we know about thrombosis and embolism comes from animal experiments, but the translation to humans is imperfect. A comparative study of platelet function across species found that mouse platelets are the most biophysically similar to human platelets in terms of adhesion and contractile force, despite being much smaller. Pig platelets adhere well to collagen but poorly to fibrinogen, while dog platelets show the reverse. Dog platelets also produce contractile forces nearly triple those of human platelets, the highest measured in any species studied.23Blood. A Comparative Medicine Study of Platelet Biophysics Among Hemostasis Models of Different Species Because platelet contractile force influences clot density and structure, results from canine models of thrombosis may not translate cleanly to human outcomes. These species-level differences are one reason promising anticlotting drugs sometimes fail or behave unexpectedly when they move from animal testing into human trials.